To assess the safety, tolerability, pharmacokinetics, and early signs of biological activity of danegaptide in patients with non-proliferative diabetic retinopathy (NPDR).
Key Findings:
The trial met objectives for safety, tolerability, and pharmacokinetics.
More than half of study eyes showed retinal imaging data indicating reduced vascular leakage.
Statistically significant reduction in edema scores by the end of the study.
Interpretation:
Danegaptide has potential as an oral therapy for NPDR, addressing a significant unmet need and possibly improving patient adherence compared to injection-based treatments.
Limitations:
Small sample size of 24 patients.
Early-stage trial results need confirmation in phase 2.
Conclusion:
If successful in phase 2, danegaptide could transform NPDR treatment by enabling earlier intervention and reducing treatment burden.
